December 02 at 12:10 pm

MicroBot Medical: Market Responds to New Patents; Scientific Advisory Board Appointments

Micro-robotic technology company, MicroBot Medical (Nasdaq: MBOT), has received two new patents for its LIBERTY Robotic System, the world’s first fully disposable robotic system for use in endovascular procedures. MicroBot was issued a design patent allowance by the US Patent & Trademark Office, covering its robotic system’s remote controller’s unique interface design. Highlights In November… [Read More]
December 01 at 5:13 pm

NeuroMetrix, Inc. To Launch First FDA-Approved Medical Device for Fibromyalgia

  Novel medical device and technology company, NeuroMetrix, Inc. (Nasdaq: NURO), will launch the first and only medical device authorized by the FDA to help reduce the symptoms of fibromyalgia. The full commercial launch of the company’s Quell® Fibromyalgia device is expected to take place in Q2 2023. A Pathfinder Program will be launched on… [Read More]
November 30 at 1:55 pm

IceCure’s ProSense® System First and Only Medicare Approved Cryoablation Procedure for Breast Cancer

  Cryoablation technology company, IceCure Medical (Nasdaq: ICCM) has received assignment to a Medicare Payment Group for hospital outpatient payment for its ProSense® System. ProSense is a minimally-invasive procedure that destroys early-stage breast cancer tumors by cryoablation (freezing). In October, IceCure filed a De Novo classification request with the FDA for breast cancer marketing authorization… [Read More]
November 21 at 3:00 pm

Lexaria Bioscience Turns Focus to Dementia and Diabetes with New Studies

Lexaria Bioscience (Nasdaq): LEXX is investigating the potential therapeutic utility of its proprietary DehydraTECHTM-CBD against dementia and diabetes, two of the world’s biggest public health crises. The global dementia drug market is projected to reach $32.3 billion by 2030 diabetes and the diabetes drug market is expected to reach $82.92 billion by 2027. Lexaria recently demonstrated… [Read More]
November 17 at 9:37 pm

Lightning eMotors (ZEV) Drops 40% As Company Enters into Exchange Agreement with Convertible Noteholders

Lightning eMotors (ZEV) an electric vehicles company fell 40% in a rough day for EV stocks. The drop also comes shortly after the Company announced they are entering into exchange agreements with certain 7.5% convertible noteholders. The Company exchanged 13.3 million newly issued shares of common stock for $14M aggregate principal amount of the Convertible… [Read More]
November 17 at 9:40 am

Asensus Surgical Leases SenhanceⓇ Surgical System to 9th German Hospital; First Pediatric Surgery Program

  Medical device company, Asensus Surgical (NYSE American: ASXC) has announced the first-ever Senhance pediatric surgery program will be initiated by a children’s hospital in Germany. The Dr. von Hauner Children’s Hospital at Ludwig Maximilians University, Munich, has entered into an agreement to lease and utilize a Senhance Surgical System. Highlights Asensus’ Senhance Surgical System… [Read More]
November 16 at 12:27 am

Exagen (XGN) Skyrockets 42% After Q3 Earnings Report

Exagen (XGN) , a medical diagnostic company, skyrocketed 42% the day after posting their Q3 earnings report. Exagen reported a quarterly loss of $0.47 per share versus the Zacks Consensus of a loss of $0.76 per share. Exagen also posted revenue of $14.73 million beating the Zacks Consensus Estimate by 61.24%. “I’m very excited to… [Read More]
November 11 at 11:27 am

Bionik Laboratories Q2 Fiscal Year 2023 Earnings: New Strategic Direction Increases Outlook for Growth; Revenue Increase of 113% YoY

  Robotics company, Bionik Laboratories Corp. (BNKL) has announced its earnings for the second quarter of fiscal year 2023, reporting a revenue increase of 113% and subscription revenue increase of 10% YoY. In September, the company began a nationwide roll-out of a network of neuro-recovery Centers of Excellence that will showcase Bionik technology and solutions…. [Read More]
November 10 at 2:45 pm

Lexaria Bioscience Initiates Studies Investigating DehydraTECHTM-CBD as a Potential Therapeutic for Dementia and Diabetes

Drug delivery innovator, Lexaria Bioscience (NASDAQ: LEXX) believes its proprietary drug delivery technology, DehydraTECH processed with cannabidiol (CBD) may have applications in the treatment of dementia and diabetes. Lexaria has previously demonstrated the safety and efficacy of DehydraTECH-CBD in human hypertension studies, and has initiated two new studies to investigate the effect of the compound… [Read More]